Promising combo may keep breast cancer from returning
NCT ID NCT02654119
First seen Jan 07, 2026 · Last updated Jun 21, 2026 · Updated 27 times
Summary
This study tested a combination of two chemotherapy drugs (cyclophosphamide and paclitaxel) plus a targeted antibody (trastuzumab) given after surgery to 20 patients with early-stage HER2-positive breast cancer. The goal was to see if this treatment is safe and can prevent the cancer from coming back. The main focus was on side effects like low white blood cell counts, nerve damage, and heart issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Faith Regional Health Services Carson Cancer Center
Norfolk, Nebraska, 68701, United States
-
Nebraska Medicine-Village Pointe
Omaha, Nebraska, 68118, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclophosphamide, paclitaxel, and trastuzumab
What this could lead to
If successful, this combination could help prevent HER2-positive breast cancer from returning after surgery.
What could go wrong
This is a small, early-phase study (20 participants) focused on safety and side effects, so it is not yet proven to be effective. Common risks include low white blood cell counts, nerve damage, and heart problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.